Topics

Human medicines European public assessment report (EPAR): Prometax, rivastigmine, Alzheimer Disease,Parkinson Disease,Dementia, Date of authorisation: 03/12/1998, Revision: 36, Status: Authorised

12:30 EDT 28 Oct 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Prometax, rivastigmine, Alzheimer Disease,Parkinson Disease,Dementia, Date of authorisation: 03/12/1998, Revision: 36, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Prometax, rivastigmine, Alzheimer Disease,Parkinson Disease,Dementia, Date of authorisation: 03/12/1998, Revision: 36, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Prometax, rivastigmine, Alzheimer Disease,Parkinson Disease,Dementia, Date of authorisation: 03/12/1998, Revision: 36, Status: Authorised"

Quick Search

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Dementia
Dementia describes a range of symptoms of cognitive decline. For example memory loss, problems with reasoning and communication skills, and a reduction in a person's abilities and skills in carrying out daily activities. There are about 820,000 peo...